Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
9.27
USD
|
-2.32%
|
|
-3.13%
|
+20.70%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
69.72
|
42.98
|
70.12
|
389.1
|
278.8
|
509
|
-
|
-
|
Enterprise Value (EV)
1 |
33.48
|
42.98
|
70.12
|
389.1
|
278.8
|
509
|
509
|
509
|
P/E ratio
|
-2.51
x
|
-1.05
x
|
-0.22
x
|
-4.19
x
|
-3.17
x
|
-5.3
x
|
-5.27
x
|
-5.01
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
611
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
611
x
|
EV / EBITDA
|
-
|
-
|
-0.36
x
|
-7.27
x
|
-3.36
x
|
-4.95
x
|
-4.04
x
|
-3.61
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-4.07
x
|
-7.83
x
|
-6.07
x
|
-5.02
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-24.6%
|
-12.8%
|
-16.5%
|
-19.9%
|
Price to Book
|
-
|
-
|
0.57
x
|
-
|
-
|
1.83
x
|
1.98
x
|
3.32
x
|
Nbr of stocks (in thousands)
|
1,966
|
3,347
|
13,009
|
26,134
|
36,296
|
54,913
|
-
|
-
|
Reference price
2 |
35.46
|
12.84
|
5.390
|
14.89
|
7.680
|
9.270
|
9.270
|
9.270
|
Announcement Date
|
3/10/20
|
3/11/21
|
3/10/22
|
3/22/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.8333
|
EBITDA
1 |
-
|
-
|
-195
|
-53.5
|
-83.03
|
-102.8
|
-126.1
|
-141.1
|
EBIT
1 |
-27.09
|
-37.44
|
-195
|
-53.5
|
-83.03
|
-103.8
|
-116.5
|
-127.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-15,345.4%
|
Earnings before Tax (EBT)
1 |
-26.29
|
-37.3
|
-194.9
|
-51.83
|
-72.89
|
-90.87
|
-110.6
|
-123.3
|
Net income
1 |
-26.29
|
-37.3
|
-194.9
|
-51.83
|
-72.89
|
-90.87
|
-110.6
|
-123.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-14,797.76%
|
EPS
2 |
-14.10
|
-12.18
|
-24.58
|
-3.550
|
-2.420
|
-1.748
|
-1.758
|
-1.850
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-68.47
|
-65
|
-83.85
|
-101.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-12,180.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/11/21
|
3/10/22
|
3/22/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-9.508
|
-15.38
|
-11.45
|
-12.39
|
-14.29
|
-13.49
|
-15.1
|
-20.24
|
-34.2
|
-24.15
|
-25.2
|
-26.2
|
-27.3
|
-
|
-
|
EBIT
1 |
-9.508
|
-15.38
|
-11.45
|
-12.39
|
-14.29
|
-13.49
|
-15.1
|
-20.24
|
-34.2
|
-24.15
|
-24.51
|
-26.78
|
-28.94
|
-32.8
|
-34.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.491
|
-15.32
|
-11.25
|
-12
|
-13.26
|
-11.19
|
-12.57
|
-17.73
|
-31.41
|
-19.93
|
-21.49
|
-23.7
|
-25.77
|
-29.98
|
-31.02
|
Net income
1 |
-9.491
|
-15.32
|
-11.25
|
-12
|
-13.26
|
-11.19
|
-12.57
|
-17.73
|
-31.41
|
-19.93
|
-21.49
|
-23.7
|
-25.77
|
-29.98
|
-31.02
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7300
|
-1.180
|
-0.8600
|
-0.8700
|
-0.7200
|
-0.4000
|
-0.4500
|
-0.6300
|
-0.9400
|
-0.3800
|
-0.3975
|
-0.4350
|
-0.4525
|
-0.4700
|
-0.4850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/12/22
|
8/9/22
|
11/10/22
|
3/22/23
|
5/11/23
|
8/7/23
|
11/13/23
|
3/4/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
36.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-68.5
|
-65
|
-83.9
|
-102
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
9.400
|
-
|
-
|
5.070
|
4.680
|
2.790
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.02
|
-
|
0.03
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/11/21
|
3/10/22
|
3/22/23
|
3/4/24
|
-
|
-
|
-
|
Last Close Price
9.27
USD Average target price
25.29
USD Spread / Average Target +172.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.70% | 509M | | +7.52% | 113B | | +11.38% | 106B | | +0.87% | 22.27B | | -12.64% | 22.22B | | -4.59% | 19.43B | | -37.85% | 17.87B | | -8.58% | 17.24B | | +7.77% | 14.29B | | +37.41% | 12.52B |
Bio Therapeutic Drugs
|